Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review

John K Triantafillidis
George Malgarinos
Inflammatory Bowel Disease Unit, IASO General Hospital, Athens, Greece

Abstract: Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder characterized by abdominal pain or discomfort and altered bowel habits. The disease affects a large part of the world population. The clinical course is mostly characterized by a cyclic recurrence of symptoms. Therefore, IBS patients should receive, as an initial therapeutic approach, a short course of treatment, and long-term treatment should be reserved for those patients with recurrent symptoms. The available clinical trials show that significant improvement of the symptoms over placebo could be achieved with various drugs, although this improvement is frequently time dependent and with high relapse rates after the cessation of the treatment. In a proportion of patients, clinically obvious relapse could appear long after stopping the treatment. Some of the available pharmacologic agents, including otilonium bromide (OB), are able to significantly prolong the time to the appearance of relapse, compared with placebo. As a consequence, some authors suggest that a cyclic treatment could be of benefit. Antispasmodic drugs have been used for many years in an effort to control the symptoms of IBS. OB is a poorly absorbed spasmyloytic drug, exerting significantly greater control of the symptoms of IBS compared with placebo. Recent data suggest that the drug could effectively be used for the long-term management of patients with IBS. The aim of this review is to provide the reader with an evidence-based overview of the efficacy and tolerability of OB in the long-term management of IBS patients, based on the results of the clinical trials published so far.

Keywords: irritable bowel syndrome, IBS, treatment, otilonium bromide

Introduction

Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder characterized by abdominal pain or discomfort and altered bowel habits. It affects about 12%–20% of the world population, having a significant negative impact on patients’ quality of life. The exact etiopathogenesis of this syndrome remains obscure, although significant progress on biochemical, psychosocial, and physiologic mechanisms has recently been achieved.1,2

During the last years, various antispasmodic drugs for the treatment of IBS have been evaluated in a number of clinical studies. Otilonium bromide (OB) is a poorly absorbed antispasmodic drug, which has significantly greater efficacy compared with placebo in controlling the symptoms of patients with IBS.3 The drug has been approved for the relief of symptoms of patients with IBS in most countries of the world, including Europe, Australia, and South and North America.

The aim of this review is to provide the reader with an overview of the efficacy and tolerability of OB in the long-term management of patients with IBS, based on...
the results of the available clinical trials. Meta-analyses were not included in this review. However, the only one available so far does not include the recently published and most important Otilonium Bromide in Irritable Bowel Syndrome (OBIS) study.5

Natural course of IBS
The natural history of IBS has not been fully elucidated. It is generally characterized by a recurrence of the symptoms, the severity of which changes over time. In most cases, the clinical course is characterized by the presence of mild to moderate symptoms, appearing sequentially. After many years, the majority of patients will still have symptoms that could change to another subtype of IBS or overlap with dyspeptic symptoms.6

IBS seems to be a heterogeneous clinical entity.7-9 Older studies have revealed that after a follow-up period ranging from 1 year to 32 years, 73% of patients still experienced symptoms.9-11 In a systematic review, Guilera et al12 concluded that the prevalence of IBS subtypes differs according to the geographical location, population studies, and criteria employed to define IBS. Mearin et al12 followed up a large cohort of IBS patients. They found that after 3 months, two-thirds of patients reported the same IBS subtype, but only half of them fell into the very same clinical pattern. In a subsequent study, the same group of investigators described that after 1-year follow-up, half of the patients and their physicians considered the IBS to have had some improvement.13 A systematic review concluded that after a median follow-up of 2 years, 30%-50% of patients with IBS had unchanged symptom severity, 2%-18% developed worse IBS, and the rest either improved or saw a disappearance of symptoms.14

The available data suggest that the pattern of IBS symptoms is cyclical. More than half of IBS patients are still symptomatic after up to 10 years, and clinical symptoms are present or disappear in days to weeks. The benefit from the treatment may extend beyond 4 weeks, but relapse rates are high (around 40% when stopping treatment after 3 months), although relapse is not always immediate after the cessation of the treatment. The benefit of treatment could be clinically obvious for more than 1 year, although the relapse rate after treatment withdrawal, following long-term (1-year) treatment, is still quite high (40%).5

OB in the treatment of IBS
General considerations of the use of OB
Patients with IBS could be conservatively managed by either short or long-term treatment. Some patients require only “single-shot” treatment, while others need treatment for a longer period. Certainly, patients with continuous symptoms require long-term treatment.

The suggestion for short-term treatment is based on the following: 1) a significant number of IBS patients improve over time and thus they do not need further treatment, 2) about 50% of patients do not relapse during the follow-up period, 3) most relapses do not occur immediately after stopping treatment, and 4) certain treatments might have long-lasting positive effects. On the contrary, the suggestion for long-term treatment of IBS patients is based on the following: 1) more than 50% of patients continue to have symptoms for months or years, 2) the favorable results of treatment continue for a long period of time, 3) relapse of symptoms after the cessation of treatment could appear in more than 50% of the treated patients, and 4) the positive results of treatment might appear several days or weeks after the initiation of treatment.15

The intensity, frequency, and specificity of the symptoms in a given patient could decisively influence the therapeutic strategy applied. Sometimes, the symptoms may be of mild, moderate, or severe intensity, requiring only reassurance in some cases, an intervention in others, and multimodal intervention in a minority of them. If the symptoms are continuous, occasional, or intermittent, then continuous, limited, or on-demand treatment could be applied, respectively. It must be emphasized that the drug of first choice is selected on the basis of the dominant symptom.15 If the treatment is unsuccessful, the drug can be changed; otherwise, it can be suspended after a limited course. If a relapse occurs, treatment should be resumed with the same drug. If, however, the patient remains in remission, he/she might not receive unnecessary treatment. Most experts agree that long-term treatment should be reserved for patients who experience recurrent symptoms, and that a cyclic treatment should be applied in all patients, being in accordance with the natural behavior of the disease.15

Chemistry and structural formula of OB
The chemical description of OB is diethylmethyl[2-{4-(2-octyloxybenzamido)-benzoyloxy]-ethyl]ammonium bromide. The molecular formula of the drug is \( \text{C}_{31} \text{H}_{43} \text{BrN}_2 \text{O}_7 \) and the molecular weight 563.6. The long aliphatic chain favors the binding of the drug to the cell membrane of the target tissue, thus increasing the duration of its pharmacologic effects. The positively charged nitrogen atom of OB is responsible for the scant systemic absorption and the poor penetration in the central nervous system.
Pharmacologic properties of OB

After oral administration, OB has poor systemic absorption thanks to physicochemical characteristics, and remains in the gastrointestinal tract acting locally. In animal models, the plasma levels of the drug were 1,000 times lower than in the gastrointestinal tract. Pharmacokinetic studies in humans have revealed that the drug was almost entirely eliminated by feces. The small absorbed fraction (3%) is rapidly eliminated from the circulation through the biliary tract. Therefore, OB is subject to enterohepatic recirculation. The drug does not cross the blood–brain barrier. Orally administered 14C-otilonium bromide is able to effectively penetrate into the large intestine walls, a recognized target for drugs oriented toward IBS therapy. OB is considered to be a paracellularly transported drug whose absorption is favored by bile salts.

An interesting point is how the drug gains access to the enteric neuromuscular apparatus to achieve its effects. In vitro studies demonstrated that OB is accumulated in its principal sites of action, namely the inner layer of the large bowel circular muscle and the submucosa. The colonic receptor binding profile of OB gives a molecular explanation for the spasmyloytic effect of the drug. A combination of antimuscarinic and Ca2+ channel blocker properties best accounts for the action of OB.

Mechanism of the action of OB

The drug exerts its action through several mechanisms determined by the presence of several receptors and chemical mediators. The drug is able to act on calcium channels, cholinergic pathways, and neurokines receptors.

Intestinal motility (calcium channels)

The drug restores physiologic motility and enhances pain threshold to various intestinal stimuli by extra- and intracellular mechanisms. At the extracellular level, OB blocks the Ca2+ fluxes in the intestinal smooth muscle cells through Ca2+ channels, acting as an antagonist of either voltage-operated Ca2+ channels or selected receptors. At the intracellular level, the drug inhibits Ca2+ release from sarcoplasmic reticulum.

Antisecretory potential (cholinergic pathways)

Acetylcholine is one of the extracellular transmitters involved in the regulation of intestinal fluid secretion. When acetylcholine binds to M3 receptors, a calcium wave generated by mobilization of calcium from intracellular stores propagates from the basis of the crypt to its apex. This stimulates an increase in chloride in the epithelium, followed by the secretion of fluid into the intestinal lumen. OB, as an anticholinergic agent, inhibits muscarinic M3 receptor-coupled calcium signals and acetylcholine-induced calcium mobilization at the level of the colonic epithelium, thus exhibiting an antisecretory potential in IBS patients with diarrhea.

Tachykinin receptors

Tachykinins play a major role in visceral nociception. In several animal studies, NK2 receptor antagonists were shown to decrease the nociceptive response to rectal and abdominal distension. OB antagonizes tachykinin receptors on the intestinal smooth muscle cells and afferent nervous terminations, thus modulating the development of intestinal hyperalgesia.

As a consequence, OB, by causing inhibition of L-/T-type calcium channels, muscarinic, and tachykinergic responses concurrently, could effectively exert its pharmacologic properties.

Physiologic effects of OB

OB has many physiologic effects on the bowel smooth muscles, such as spontaneous and triggered contractions and visceral hypersensitivity.

Effect on bowel motility and smooth muscles

OB inhibits basal and stimulated gastrointestinal motility in response to contracting agents of different natures, either chemical or physical. A combination of Ca2+ channel blocking properties and mild antimuscarinic effects explains the pharmacologic action of the drug. In the micrometer range of concentrations, OB acts as a muscarinic and tachykinin NK1 receptor antagonist and as a calcium channel blocker. The latter property is likely to account for its ability to suppress contraction initiated by the tachykinin NK1 receptor agonist. Therefore, multiple mechanisms of action account for the ability of OB to reduce stimulated motility of intestinal smooth muscle. OB antagonizes the internalization of the NK2 receptor in the human colon. Functional studies showed a significant increase in maximal contraction induced by NK3 agonist, and chronic exposition to OB significantly affects the NK3/SP/NO circuit. Gallego et al showed that OB strongly inhibited the main patterns of human sigmoid motility in vitro by blocking calcium influx through L-type calcium channels on smooth muscle cells. OB inhibits the spontaneous and triggered muscular contractions via inhibition
Reduction of visceral hypersensitivity

Visceral hypersensitivity seems to play a significant role in the development of symptoms in IBS patients. OB reduces visceral hypersensitivity by enhancing sensory thresholds to rectosigmoid distension. Czimmer et al. investigated patients with IBS by synectics visceral stimulator barostat, using rapid phasic distension. The pressure threshold of pain was significantly higher 1 week after treatment. The pressure and volume thresholds for maximum tolerable volume were significantly increased by 1-week OB treatment.

Clinical pharmacology and efficacy of OB

OB is used as an antispasmodic for treating spastic painful conditions of the intestinal tract, including IBS. It is also effective in reducing intestinal spasm during endoscopy. A reduction in the hypermotility induced by several stimuli has been observed both in healthy subjects and in patients with IBS. In IBS patients, OB significantly reduced the magnitude and duration of the impaired gastrocolonic response to food. OB is able to antagonize delayed and greater motility in IBS patients. The effect of the drug on the intensity of pain could be obvious after the first day of administration with standard therapeutic dose, increasing gradually thereafter.

The efficacy of OB in patients with IBS has been documented in a large number of clinical trials, in the majority of which the standard therapeutic dose of 40 mg three times a day was used. The first study, which demonstrated the efficacy of OB in patients with IBS, diarrhea variant, is that of Battaglia et al. The authors conducted a double-blind, placebo-controlled, randomized, 15-week study in patients with IBS on a 0–3 score scale with the following efficacy parameters: symptoms (abdominal pain intensity, distension, bowel habits, pain frequency, diarrhea/constipation severity, means of evacuation during days of evacuation, days without evacuation, mucus in stool, consistency of stool, sensation of incomplete evacuation, difficulty in evacuation), investigator objective signs (tenderness of sigmoid colon, pain evocation), quality of life (on a visual analog scale, ranked 0–10), and global assessment of efficacy by the investigators. After a 2-week placebo run-in, 325 patients were randomly assigned to receive either OB 40 mg three times daily or placebo for 15 weeks. The reduction in the number of abdominal pain episodes was significantly higher in OB patients (55.3%) than in those taking placebo (39.9%), as was the severity of abdominal distension (42.0% versus [vs] 30.2%; \(P<0.05\)). The visual analog scale revealed a significant improvement (\(P<0.05\)) in patients taking OB. The investigators’ global positive assessment was in favor of OB (65.2%) compared with placebo (49.6%) (\(P<0.01\)).

Glende et al. conducted a double-blind, placebo-controlled, parallel-group study in 378 IBS patients who were treated for 15 weeks with 40 mg OB or placebo three times daily. The rate of response to treatment within 2–4 months (primary endpoint) was significantly higher in the OB group (36.9%) than in the placebo group (22.5%; \(P=0.007\)). Also, the total monthly and weekly responses to the single endpoints were significantly more frequent in the OB group than in the placebo group. Considering the three major endpoints (pain intensity, pain frequency, and presence of meteorism and distension), OB showed significantly higher proportions of responders compared with placebo. Finally, OB exerts a relevant antisecretory effect on human colonic crypts, offering additional benefits in patients with diarrhea.

Baldi et al. described a significant improvement of abdominal pain and bloating with OB vs placebo. Seventy-two patients with IBD complaining mainly of abdominal pain were studied in a double-blind trial. OB in a dose of 40 mg three times daily was compared with placebo. OB significantly reduced pain and bloating, and significantly increased the pain threshold throughout treatment. Sigmoid motility during distension was significantly reduced after OB, but it did not change after placebo.

A study performed in 117 Asian IBS patients meeting Rome II criteria showed that OB exhibited similar efficacy compared with mebeverine in reducing abdominal pain, flatulence, and abdominal bloating.

Compared with pinaverium bromide, OB seems to be more effective in reducing the number of pain attacks. Also, the combination of OB with diazepam probably increases the beneficial effect by reducing the level of anxiety. Finally, the meta-analysis of Lesbros-Pantoflickova et al. showed that improvement of IBS symptoms with all antispasmodic drugs was maintained only for OB but on the basis of only two studies.

Table 1 shows the results of the main studies related to the use of OB in IBS patients.

Long-term studies on the efficacy of OB in IBS patients

The OBIS study confirmed the efficacy of OB during and following treatment in patients with IBS. In this study, 356 patients with IBS meeting Rome II criteria participated...
### Table 1: Main studies of otilonium bromide (OB) for the treatment of irritable bowel syndrome (IBS)

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Endpoints</th>
<th>Treatment</th>
<th>Main findings</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clavé et al</td>
<td>356 patients (46.1±19 years, 71% female) with IBS</td>
<td>Primary endpoint: weekly frequency of episodes of abdominal pain at the end of the treatment period</td>
<td>OB (40 mg three times daily) vs placebo for 15 weeks</td>
<td>OB and placebo reduced abdominal pain and IBS symptoms</td>
<td>OB is safe, well tolerated, and superior to placebo in reducing the frequency of abdominal pain, severity of abdominal bloating, and protecting from symptom relapse</td>
</tr>
<tr>
<td>Chang FY</td>
<td>117 IBS patients (Rome II criteria) Double-blind, active-controlled study</td>
<td>Primary endpoint: net changes of abdominal pain/discomfort frequency score</td>
<td>OB 40 mg vs mebeverine 100 mg (three times daily)</td>
<td>Compared with baselines in per protocol populations, the reduced APDFSs in OB and mebeverine were 0.55±1.20 (P=0.011) and 0.37±1.11 (P=0.042), respectively</td>
<td>In Asian patients with IBS, OB is as effective as mebeverine for alleviating IBS symptoms</td>
</tr>
<tr>
<td>Glende et al</td>
<td>378 patients, treated for 15 weeks Double-blind, placebo-controlled, parallel-group study</td>
<td>Primary endpoint: rate of response to treatment within 2-4 months (12 single efficacy endpoints)</td>
<td>OB 40 mg or placebo (three times daily)</td>
<td>Rate of response to treatment: higher in the OB (36.9%) vs placebo (22.5%; P=0.007) group In each month of treatment, the rate of response was higher in the OB vs placebo (P&lt;0.05) group Total monthly and weekly responses to the single endpoints: significantly more frequent in OB vs placebo</td>
<td>OB is more effective than placebo, being very efficient in relieving pain and discomfort</td>
</tr>
<tr>
<td>Battaglia et al</td>
<td>378 patients 15-week, double-blind, randomized, placebo-controlled, parallel study</td>
<td>Symptoms, investigator objective signs, quality of life, and global assessment of efficacy</td>
<td>OB 40 mg (three times daily) vs placebo</td>
<td>Reduced pain episodes (P&lt;0.01), distension (P&lt;0.05), improved well-being (P&lt;0.05), and global symptoms (P&lt;0.01)</td>
<td>The study clearly demonstrated the efficacy of OB in patients with IBS</td>
</tr>
<tr>
<td>Vilagrasa et al</td>
<td>114 patients, 24-month, randomized, open-label, parallel study</td>
<td>Abdominal pain, abdominal distension, bowel movements were evaluated before treatment, at the end, and after 12 months</td>
<td>OB 40 mg (three times daily) vs 20 g fiber, 10 g bran</td>
<td>Improved pain and distension (P&lt;0.01) OB vs placebo; improved pain/distension (NS) roughage vs placebo</td>
<td>OB more effective than a high-fiber diet in the treatment of IBS</td>
</tr>
<tr>
<td>Baldi et al</td>
<td>72 patients, 4-week, double-blind, placebo-controlled, parallel study</td>
<td>Clinical evaluation (symptom variations) and functional studies (sigmoid manometry during bowel distension)</td>
<td>OB 40 mg (three times daily) vs placebo</td>
<td>Improved pain and bloating (P&lt;0.02); frequency of bowel movements (NS)</td>
<td>OB improves symptoms and reduces stimulated motor activity of the sigmoid</td>
</tr>
</tbody>
</table>

Abbreviations: APDFSs, abdominal pain/discomfort frequency score; NS, not significant; vs, versus.
in a double-blind, randomized, parallel, placebo-controlled, Phase IV study. OB (40 mg three times daily) or placebo was administered for 15 weeks. Patients who completed the 15-week period were subsequently allocated to a 10-week follow-up without receiving any drug therapy. The follow-up was extended for 10 more weeks. A total of 179 patients were assigned to 15 weeks of treatment with OB and 177 to placebo.

The results showed that although both OB and placebo reduced abdominal pain and IBS symptoms, the effect of OB was significantly greater in the reduction of weekly frequency of episodes of abdominal pain at the end of the treatment period (primary endpoint −0.90±0.88 vs −0.65±0.91, P=0.03), reduction of abdominal bloating (−1.2±1.2 vs −0.9±1.1, P=0.02) and global efficacy by patient assessment (1.3±1.1 vs 1.0±1.1, P=0.047). Intensity of abdominal pain, proportion of patient responders, safety, and quality of life scores were similarly affected by OB and placebo. During the follow-up period, the therapeutic efficacy of OB remained greater than placebo in terms of withdrawal rate due to symptom relapse (10% vs 27%, P=0.009), global efficacy of treatment, and relapse-free probability (P=0.038).

This study showed that OB, apart from being superior to placebo in reducing both abdominal pain and bloating, was able to protect against the appearance of symptom relapse in IBS, as the results obtained with OB at the end of the treatment period also persisted during the follow-up. It is possible that the chemical characteristics of OB and its affinity for colonic smooth muscle may be the decisive factors influencing the prolonged benefit of the drug, which was not observed with other spasmyloytic drugs. Obviously, this effect is of major importance in the clinical management of patients with IBS, especially if the intermittent kind of therapy has been chosen. Finally, the OBIS study showed that relapse rates in IBS patients varied considerably. This fact supports the suggestion of treating patients with intermittent or cyclic mode.16-40 However, the optimal long-treatment strategy has not yet been elucidated (Table 1).

In another study, which included 114 patients with IBS, OB in the suggested dose (40 mg three times daily, n=61) was more effective than a diet that included daily 20 g of fiber and 10 g of bran (n=53). OB resulted in an improvement in pain and abdominal distension towards pretreatment significantly higher compared with the results of the diet alone at the end of 24 months of follow-up (P<0.01).41

**Adverse effects – safety**

As OB is poorly absorbed, it mainly acts at a local level, a characteristic explaining the almost absence of significant side effects.

**Acute toxicology**

No fatalities occurred when the drug was administered orally at doses up to 1,500 mg/kg and 1,000 mg/kg in rats and dogs, respectively.

**Chronic toxicity in animal models**

In animal models, OB has proven minimal toxicity, and overdose should not be a concern. In addition, no embryotoxicity, teratogenic, or mutagenic effects were observed in animal studies. Oral doses of 80 mg/kg of OB administered to laboratory animals for 180 days did not cause any changes in blood chemistry or histologic profiles. No embryotoxicity or teratogenic effects were observed in rats or rabbits at doses up to 60 mg/kg. No mutagenic effects were observed.

**Chronic toxicity in humans**

In humans, OB has a placebo-like tolerability without systemic anticholinergic effects. The spasmyloytic activity of the drug on the gastrointestinal tract is evident at doses that neither affect the gastric secretion nor produce atropine-like side effects. So far, almost no side effects were associated with the use of OB. In fact, two trials did not report any adverse effect.41,42 Mild nausea was reported in another study.46 Comparisons with other spasmyloytic agents showed low incidence of weakness and dizziness for OB.38 Concerning dropouts, a placebo-controlled study revealed two in the OB group compared with one in the placebo group.44 Data from safety and postmarketing observation showed that OB is well tolerated and that side effects do not differ with those seen with placebo. In fact, after 10 years, only two adverse reactions (urticaria) have been reported.41 No drug interactions have been reported to date. OB can be given safely to patients with hepatic, renal, and cardiac disease.

**Conclusion**

OB possesses distinct smooth muscle favorable properties and effects on visceral perception. It shows a localized activity, as it is poorly absorbed and selectively taken up in the lower gastrointestinal tract. The drug reduces abdominal pain and discomfort in patients with IBS. The efficacy and tolerability of OB are better compared with both placebo and other similar drugs. Long-term treatment could be safely and effectively applied in most patients with IBS.

**Disclosure**

The authors report no conflicts of interest in this work.
References
